JP2001509492A5 - - Google Patents

Download PDF

Info

Publication number
JP2001509492A5
JP2001509492A5 JP2000501781A JP2000501781A JP2001509492A5 JP 2001509492 A5 JP2001509492 A5 JP 2001509492A5 JP 2000501781 A JP2000501781 A JP 2000501781A JP 2000501781 A JP2000501781 A JP 2000501781A JP 2001509492 A5 JP2001509492 A5 JP 2001509492A5
Authority
JP
Japan
Prior art keywords
group
compound
hexose
composition
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000501781A
Other languages
English (en)
Japanese (ja)
Other versions
JP4460148B2 (ja
JP2001509492A (ja
Filing date
Publication date
Priority claimed from US08/889,355 external-priority patent/US7002027B1/en
Application filed filed Critical
Publication of JP2001509492A publication Critical patent/JP2001509492A/ja
Publication of JP2001509492A5 publication Critical patent/JP2001509492A5/ja
Application granted granted Critical
Publication of JP4460148B2 publication Critical patent/JP4460148B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2000501781A 1997-07-08 1998-07-08 治療用薬剤の細胞への送達を増強するための組成物および方法 Expired - Fee Related JP4460148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use
US08/889,355 1997-07-08
PCT/US1998/014241 WO1999002191A1 (en) 1997-07-08 1998-07-08 Compositions and methods for enhancing delivery of therapeutic agents to cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009293390A Division JP2010070565A (ja) 1997-07-08 2009-12-24 治療用薬剤の細胞への送達を増強するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2001509492A JP2001509492A (ja) 2001-07-24
JP2001509492A5 true JP2001509492A5 (https=) 2006-01-05
JP4460148B2 JP4460148B2 (ja) 2010-05-12

Family

ID=25394956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000501781A Expired - Fee Related JP4460148B2 (ja) 1997-07-08 1998-07-08 治療用薬剤の細胞への送達を増強するための組成物および方法
JP2009293390A Withdrawn JP2010070565A (ja) 1997-07-08 2009-12-24 治療用薬剤の細胞への送達を増強するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009293390A Withdrawn JP2010070565A (ja) 1997-07-08 2009-12-24 治療用薬剤の細胞への送達を増強するための組成物および方法

Country Status (20)

Country Link
US (3) US7002027B1 (https=)
EP (2) EP1011733B1 (https=)
JP (2) JP4460148B2 (https=)
KR (1) KR100691572B1 (https=)
AR (1) AR016312A1 (https=)
AT (2) ATE497786T1 (https=)
AU (1) AU774338B2 (https=)
CA (1) CA2294709C (https=)
CY (1) CY1109367T1 (https=)
DE (2) DE69840932D1 (https=)
DK (1) DK1011733T3 (https=)
ES (2) ES2328094T3 (https=)
HU (1) HUP0002683A3 (https=)
IL (1) IL133929A0 (https=)
MY (1) MY138257A (https=)
NZ (1) NZ502060A (https=)
PT (1) PT1011733E (https=)
TW (1) TW490306B (https=)
WO (1) WO1999002191A1 (https=)
ZA (1) ZA986003B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
WO1999052858A2 (en) * 1998-04-08 1999-10-21 Celltech Therapeutics Limited Lipids
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
SG133594A1 (en) * 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2009136396A2 (en) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines for therapy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
WO2026077967A1 (en) 2024-10-08 2026-04-16 Ferring International Center Sa Method for making syn3

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) * 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
DE69233725T2 (de) 1991-06-28 2009-02-12 The Regents Of The University Of Michigan, Ann Arbor Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) * 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JPH07109983A (ja) * 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
WO1995010265A1 (en) 1993-10-15 1995-04-20 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) * 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
WO1997005209A1 (en) * 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6283940B1 (en) * 1997-08-29 2001-09-04 S. Grant Mulholland Catheter
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
KR100499787B1 (ko) * 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
SG133594A1 (en) * 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors

Similar Documents

Publication Publication Date Title
JP2001509492A5 (https=)
US8367631B2 (en) Pharmaceutical composition which improves in vivo gene transfer
US9987232B2 (en) Dissolution aids for oral peptide delivery comprising a biguanide
JP2021523916A (ja) メッセンジャーｒｎａの皮下送達
US6559129B1 (en) Cationic liposomal delivery system and therapeutic use thereof
US20120282343A1 (en) Compositions for oral gene therapy and methods of using same
JP2010070565A5 (https=)
CN1198675A (zh) 含有hgf基因的药物
US7303762B2 (en) Absorption enhancers
CA2294709A1 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
JPH0747543B2 (ja) アシアロ糖蛋白抱合薬剤
US20110045061A1 (en) Gene therapy for diabetic ischemic disease
JP2006523662A (ja) Ｂｈｔ、ｂｈａまたは没食子酸プロピルなどの吸収促進剤
TW200930811A (en) Transfection reagent and method for enhancing transfection efficiency
JP2003528138A5 (https=)
Sewell et al. Optimizing suicide gene therapy for head and neck cancer
JPWO2001032220A1 (ja) 糖尿病性虚血性疾患遺伝子治療
CN120754284A (zh) 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒
KR20250007544A (ko) CIDEB를 표적화하는 siRNA를 이용하여 간 질환을 치료하기 위한 조성물 및 방법
WO2024124232A1 (en) Nucleic acid based cancer vaccine and methods thereof
CN112316153A (zh) 一种抗肿瘤的药物组合物及其应用
CN117159725B (zh) 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法
JP2003531181A (ja) 核酸を細胞に投与するための粒状複合体
JP4831551B2 (ja) 非虚血性心筋障害に対する医薬
JP2003531181A6 (ja) 核酸を細胞に投与するための粒状複合体